What patients want the FDA to consider about the role of AI in medicine

Federal regulators have cleared dozens of AI products used in health care, which might give the impression that the Food and Drug Administration has a firm handle on a technology that is already changing how patients are treated. But a meeting on AI regulation last week told a different story. The agency is still grappling with fundamental questions about algorithmic bias, data transparency, and how to ensure that patients benefit equally from AI's rapid progress in medicine. Unlock this article by subscribing to STAT and enjoy your first 30 days free! STAT is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.